Director, Business Development, World Wide Licensing and Acquisitions
Dr. Steven Xanthoudakis received his doctoral degree from the Department of Microbiology and Immunology at McGill University in 1990. Following his post-doctoral training at the Roche Institute of Molecular Biology in New Jersey, he assumed the position of Research Investigator in the Department of Neurogenetics at Hoffman La Roche. He was recruited back to Montreal in 1996 to join Merck Frosst Canada as a Senior Research Scientist where he focused on advancing several early stage drug discovery programs in the Neuroscience, Respiratory and Cardiovascular disease areas. Since early 2007 he has been involved in coordinating Merck Canadian and LATAM R&D out-reach programs. In his current position as Director, Business Development, Licensing and Acquisitions for Merck Research Laboratories, his primary role is to build lasting relationships with the venture capital, biotechnology and academic research communities and to help foster partnering opportunities which fit with Merck’s strategic research and development goals across all therapeutic and technology areas. He has been instrumental in establishing a number of strategic alliances with Canadian Biotech Companies including Alectos Therapeutics, EnWave Corporation, Xenon Pharmaceuticals and Zymeworks, He currently manages the Merck venture capital partnerships with Lumira Capital and Amorchem Financial. He is also the acting Chair of the CQDM Strategic Orientation Committee. Dr. Steven Xanthoudakis is based out of the Merck Canada head office in Montreal, Canada.